Company Profile: SiNON Therapeutics

CED Life Science Conference 2017 - Lightning Round & Innovation Room                                                                                       
Sub-sector: Drug Delivery                                                                
Year Founded: 2014

SiNON Therapeutics has developed a novel method of crossing the blood brain barrier, which is effective, non-invasive, and most importantly can be utilized by almost all drugs (making even retroactive application possible). It is a platform technology. SiNON is dedicated to improving the lives of those who suffer from debilitating neurological diseases by increasing the ability of drugs to cross the Blood Brain Barrier (BBB). Our patented nanoparticle, the Carbon Dot, will enable pharmaceutical companies to encapsulate their drugs in a way, which dramatically improves drug-localization to the brain. This allows for a reduction in overall dose administration to the patient, leading to reduced toxicity risk and side effects while improving therapeutic index and cost-efficacy. What makes our delivery mechanism so unique is that due to its amphiphilic nature it can passively diffuse across the BBB. Considering the rapid growth of the senior population, and subsequent increase in neurological disease, we believe that our novel technology is an essential part of the overall solution to this healthcare crisis.

Afreen Allam, Founder and CEO
Dr. S. Sarkar, Chief Scientific Officer
Abdul Allam, Director of R&D
Dr. Bholanath Pakhira, Lead PhD Researcher
Dr. Sameer Berry, Medical Liaison
Suleman Sheikh, Medical Liaison


  • Funding: $675,000
  • First place winner of Duke Start-up challenge
  • Winner of Duke Angel Award
  • Completed animal toxicity studies
  • Excretion pattern studies
  • Invited to present at World Innovation & Entrepreneurship Conference in Kunshan, China

CED, Duke Innovation and Entrepreneurship Initiative, First Flight Venture Center, SBTDC

Afreen Allam

Learn more about the CED Life Science Conference.